GoodRx reports Q2 2024 revenue $200.6M, net income $6.7M, adjusted EBITDA $65.4M

GoodRx Holdings, Inc.

2024-Q2 EPS reported $0.01 revenue$398,490,000

Revenue and Adjusted Revenue of $200.6M for Q2 2024.
Net income of $6.7M (3.3% margin); Adjusted Net Income of $32.4M (16.1% margin).
Adjusted EBITDA of $65.4M (32.6% margin).
Net cash from operations $9.7M; over 7M consumers of prescription offerings.
Interim CEO Scott Wagner noted progress in retail/PBM partnerships and brand medication scaling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.